Skip to main content Accessibility help
×
Hostname: page-component-76fb5796d-zzh7m Total loading time: 0 Render date: 2024-04-27T22:25:55.814Z Has data issue: false hasContentIssue false

5 - Pharmacological therapy

from Part I - Therapeutic interventions

Published online by Cambridge University Press:  22 August 2009

M. Dominic Beer
Affiliation:
Oxleas NHS Foundation Trust
Stephen M. Pereira
Affiliation:
Goodmayes Hospital, Essex
Carol Paton
Affiliation:
Oxleas NHS Foundation Trust
Chike I. Okocha
Affiliation:
Consultant Psychiatrist, Tarn PICU, Oxleas NHS Foundation Trust, Oxleas House, Queen Elizabeth Hospital, Woolwich, London, UK
Get access

Summary

General principles

In the past few decades, drugs have become the cornerstone of treatment for mental disorders. With the refinement of diagnostic categories and the development of newer drugs it has become important to have guidelines underpinning such treatments.

These guidelines are largely based on assumptions such as the existence of:

  • clear-cut diagnostic categories

  • effective drug treatments

  • disorders that are either life-long or represent life-long vulnerabilities

A further important assumption is that exacerbations and recurrences are unfavourable for patients, their families and society.

In intensive care psychiatry, treatment goals are generally short-term although, where appropriate, long-term goals can also be set. These goals are to reduce symptoms as rapidly as possible; build an alliance for long-term management; educate the patient and their families about the illness, its treatment, and its course (treated and untreated); and lay the groundwork for a return to premorbid levels of functioning.

Effective strategies for achieving these goals include:

  • the use of medication in adequate doses for adequate durations before abandoning a drug trial

  • avoiding polypharmacy where possible

  • optimising long-term drug treatment regimes

  • combining drug treatment with psychological treatment strategies, and providing systematic psycho-education for patients and their families

Although the ideal duration of treatment for mental disorders remains debatable, it is generally accepted that almost all acute treatments should continue for at least 6 months, and with disorders such as schizophrenia it may take 18 months, until symptom remission. Furthermore it is recommended that a discrete 6-month period of remission passes before tapering of therapeutic medication commences.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Abrams, R. 1992 Electroconvulsive Therapy. New York: Oxford University Press
Allison, DB, Mentore, JH, Heo, Met al. 1999 Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156(11): 1686–1696Google Scholar
American Psychiatric Association. 1994 Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Arlington, VA: American Psychiatric Association
American Psychiatric Association Task Force on ECT. 1990 The Practice of ECT: Recommendations for Treatment, Training, and Privileging. Washington, DC: American Psychiatric Press
Atkin, K, Kendall, F, Gould, D. 1996 Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 169: 483–488Google Scholar
Baastrup, PC, Paulsen, JC, Schou, M, Thomsen, K, Amidsen, A. 1970 Prophylactic lithium: double-blind discontinuation in manic-depressive and recurrent depressive disorders. Lancet ii: 326–330Google Scholar
Ballenger, JC, Post, RM. 1980 Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry 137: 782–790Google Scholar
Barnes, TRE, Bridges, PK. 1980 Disturbed behaviour induced with high-dose antipsychotic drugs. Br Med J 281: 274–275Google Scholar
Bauer, MS, Calabrese, JR, Dunner, DL. 1994 Multisite data vs analysis: validity of rapid cycling as a course modifier for bipolar disorder in DSM-IV. Am J Psychiatry 151: 506–515Google Scholar
Beasley, CM Jr, Tollefson, G, Tran, P. 1996a Olanzapine versus placebo and haloperidol. Acute phase results of the North American double-blind olazapine trial. Neuropsychopharmacology 14: 11–1123Google Scholar
Beasley, CM Jr, Sanger, T, Satterlee, W. 1996b Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 124: 159–167Google Scholar
Beasley, CM Jr, Hamilton, SH, Crawford, AM. 1997 Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 7: 125–137Google Scholar
Bellack, AS, Mueser, KT. 1993 Psychosocial treatment for schizophrenia. Schizophr Bull 19: 317–336Google Scholar
Bersani, G, Bressa, GM, Meco, G. 1990 Combined 5HT2 and dopamine D2 antagonism in schizophrenia: clinical, extrapyramidal and human neuroendocrine response in a preliminary study with risperidone. Hum Psychopharmacol 5: 225–231Google Scholar
Biederman, J, Lerner, Y, Belmaker, RH. 1979 Combination of lithium carbonate and haloperidol in schizoaffective disorder: a controlled study. Arch Gen Psychiatry 36: 327–333Google Scholar
Boyer, P, Lecrucibier, Y, Puech, AJ. 1995 Treatment of negative symptoms of schizophrenia with amisulpride. Br J Psychiatry 166: 68–72Google Scholar
Bradford, JM. 1983 Research on sex offenders. Psychiatr Clin North Am 6(4): 715–731Google Scholar
Brandon, S, Cowley, P, McDonald C, , Neville, P. 1984 Electroconvulsive therapy: results in depressive illness from the Leicestershire trial. Br Med J 288: 22–25Google Scholar
Breier, A, Meehan, K, Birkett, Met al. 2002. A double-blind, placebo-controlled dose–response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 59(5): 441–448CrossRefGoogle Scholar
Brenner, HD, Dencker, SJ, Goldstein, M. 1990 Defining treatment refractoriness in schizophrenia. Schizophr Bull 16: 551–561Google Scholar
Brody, D, Adler, , Kim, T. 1990 Effects of buspirone in seven schizophrenic subjects. J Clin Psychopharmacol 10: 68–69Google Scholar
Cardoni, AA. 1995 Risperidone: review and assessment of its role in the treatment of schizophrenia. Ann Pharmacother 29: 610–618Google Scholar
Carman, JS, Bigelow, LB, Wyatt, RJ. 1981 Lithium combined with neuroleptics in chronic schizophrenia and schizoaffective patients. J Clin Psychiatry 42: 124–128Google Scholar
Castelao, JF, Ferrerira L, , Gelders, YG, Heylen, SLE. 1989 The efficacy of the D2 and 5HT2 antagonist risperidone in the treatment of chronic psychoses. An open dose finding study. Schizophr Res 2: 411–415Google Scholar
Cavallero, R, Colombo, C, Smeraldi, E. 1995 A pilot, open study on the treatment of refractory schizophrenia with risperidone and clozapine. Hum Psychopharmacol 10: 231–243Google Scholar
Chouinard, G, Jones, B, Remington, G. 1993 A canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13: 35–40Google Scholar
Chouinard, G, Vainer, JL, Belanger, MC. 1994 Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis. Prog Neuropsychopharmacol Biol Psychiatry 18: 1129–1141Google Scholar
Claus, A, Bollen, J, Cuyper, H. 1992 Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatient: a multi-centre double-blind comparative study. Acta Psychiatr Scand 85: 295–305Google Scholar
Cohen, NJ, Cohen, NH. 1974 Lithium carbonate, haloperidol and irreversible brain damage. J Am Med Assoc 230: 1283–1287Google Scholar
Committee on the Safety of Medicines. 1990 Cardiotoxic effects of Pimozide. Current Problems No. 29
Cooper, AJ. 1986 Progestogens in the treatment of male sex offenders: a review. Can J Psychiatry 31(1): 73–79Google Scholar
Cooper, T. 1996 Clozapine plasma level monitoring: current status. Psychiatr Q 67: 297–311Google Scholar
Coppen, A, Noguera, R, Bailey, J. 1971 Prophylactic lithium in affective disorders: a controlled trial. Lancet ii: 326–330Google Scholar
Daniel, DG, Whitcomb, . 1998 Treatment of the refractory schizophrenic patient. J Clin Psychiatry 59 [Suppl 1]: 13–19Google Scholar
Davidson M, Emsley R, Kramer M et al. 2007 Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6 week, randomised, placebo-controlled study. Schizophr Res 10.1016/j.schres.2007.03.003
Davis, H, Squire, L 1984 Protein synthesis and memory. Psychol Bull 96: 518–559Google Scholar
Davis, JMet al. 1994 Depot antipsychotic drugs: place in therapy. Drugs 47: 120–127Google Scholar
Devanand, DP, Dwork, AJ, Hutchinson, ER, Bolwig, TG, Sackeim, HA. 1994 Does electroconvulsive therapy alter brain structure?Am J Psychiatry 151: 957–970Google Scholar
Devinsky, O, Honigfield, G, Patin, J. 1991 Clozapin-related seizures. Neurology 41: 369–371Google Scholar
Dunner, DL, Fieve, RR. 1974 Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 30: 229–233Google Scholar
Emrich, HM, Dose, M, Serssen D, . 1985 The use of sodium valproate and oxycarbamazepine in patients with affective disorders. J Affect Disord 8: 243–250Google Scholar
Faedda, GL, Baldessarini, RJ, Tohen, M, Strakowski, SM, Waternaux, C. 1991 Episode sequence in bipolar disorder and response to lithium treatmentAm J Psychiatry 148: 1237–1239Google Scholar
Fieve, RR, Kumbaraci, T, Dunner, DL. 1976 Lithium prophylaxis of depression in bipolar I, bipolar II, and unipolar patients. Am J Psychiatry 133: 925–930Google Scholar
Fink, M. 1990 How does ECT work?Neuropsychopharmacology 3: 77–82Google Scholar
Fink, M. 1994 Indications for the use of ECT. Psychopharm Bull 30(3): 269–280Google Scholar
Fontaine, KR, Heo, M, Harrigan, EPet al. 2001 Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res 101(3): 277–288Google Scholar
Fowler, NO, McCall, D, Chuan, T. 1976 Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs. Am J Cardiol 37: 223–230Google Scholar
Freeman, CPL, Basson, JV, Creighton, A. 1978 Double-blind controlled trial of electroconvulsive ttherapy (ECT) and simulated ECT in depressive illness. Lancet i: 738–740Google Scholar
Freeman, TW, Clothier, JL, Passaglia, P, Lesem, MD. 1992 A double blind comparison of VPA and LI in the treatment of acute mania. Am J Psychiatry 149: 108–111Google Scholar
Geoff, DG, Brotman, AW, Waites, M, McCormick, S. 1990 Trial of fluoxetine added to neuroleptics for treatment resistant schizophrenic patients. Am J Psychiatry 147: 492–494Google Scholar
Goodnick, PJ, Jerry, JM. 2002 Aripiprazole: profile on efficacy and safety. Expert Opin Pharmacother 3(12): 1773–1781Google Scholar
Goodwin, FK, Jamison, KR. 1990 Manic-depressive illness. New York: Oxford University Press
Gregory, S, Shawcross, CR, Gill, D. 1985 The Nottingham ECT study: a double blind comparison of bilateral, unilateral, and simulated ECT in depressive illness. Br J Psychiatry 146: 520–524Google Scholar
Hakola, HP, Laulumaa, VA. 1982 Carbamazepine in treatment of violent schizophrenics [Letter]. Lancet ii: 1358Google Scholar
Harrington, M, Lelliott, P, Paton, C, Okocha, C, Duffett, R, Sensky, T. 2002a The results of a multi-centre audit of the prescribing of antipsychotic drugs for in-patients in the United Kingdom. Psychiatr Bull 26: 414–418Google Scholar
Harrington, M, Lelliott, P, Paton, C, Konsolaki, M, Sensky, T, Okocha, C. 2002b Variation between services in polypharmacy and combined high dose of antipsychotic drugs prescribed for in-patients. Psychiatr Bull 26: 418–420Google Scholar
Hasegawa, M, Gutierrez-Esteinou, R, Way, L, Meltzer, HY. 1993 Relationship between clinical efficacy and clozapine plasma concentrations in schizophrenia: effect of smoking. J Clin Psychopharmacol 13: 383–390Google Scholar
Hayes, SG. 1989 Longterm use of VPA in primary psychiatric disorders. J Clin Psychiatry 50: 35–39Google Scholar
Hegarty, JDet al. 1994 One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 151: 1409–1416Google Scholar
Henderson, DC, Cagliero, E, Gray, Cet al. 2000 clozpinel, diabetes mellitus, weight gain and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 157(6): 975–981Google Scholar
Hirsch, SR, Barnes, TRE. 1994 Clinical use of high-dose neuroleptics. Br J Psychiatry 164: 94–96Google Scholar
Hirsch, SR, Link, CGG, Goldstein, JM. 1996 ICI204,636: a new atypical antipsychotic drug. Br J Psychiatry 168 [Suppl 29]: 45–56Google Scholar
Hirschowitz, J, Casper, R, Garver, DL. 1980 Lithium response in good prognosis schizophrenia. Am J Psychiatry 137(8): 916–920Google Scholar
Ital, T, Keskiner, A, Heinemann, L. 1970 Treatment of resistant schizophrenics with extreme high dosage fluphenazine. Psychosomatics 11: 496–491Google Scholar
Johnstone, EC, Deakin, JFW, Lawler, P, Frith, CD. 1980 The Northwick Park electroconvulsive therapy trial. Lancet ii: 1317–1320Google Scholar
Jusic, N, Lader, M. 1994 Post-mortem antipsychotic drug concentrations and unexplained deaths. Br J Psychiatry 165: 787–791Google Scholar
Kallen, B, Tandberg, A. 1983 Lithium and pregnancy – a cohort study of manic-depressive women. Acta Psychiatr Scand 62: 134–139Google Scholar
Kane, J, Honigfield, G, Singer, J, Meltzer, HY. 1988 The clozaril collaboration study group. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789–796Google Scholar
Kane, JM. 1992 Clinical efficacy of clozapine in treatment refractory schizophrenia: an overview. Br J PsychiatrySuppl 17: 41–45Google Scholar
Kane, JM, Marder, SR. 1993 Psychopharmacological treatment of schizophrenia. Schizophr Bull 19: 287–302Google Scholar
Kane, J, Canas, F, Kramer, Met al. 2006 Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial. Schizophr Res 90: 147–161Google Scholar
Kapur, S.Remington, G. 2000 Atypical antipsychotics. Patients value the lower incidence of extrapyramidal side effects. Br Med J 321: 1360–1361Google Scholar
Kapur, S, , Seeman P.2001 Does fast dissociation from dopamine D2 receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 158: 360–369
Karliner, W. 1994 Maintenance ECT. Convuls Ther 10: 238–242Google Scholar
Karson, CN, Weinberger, DR, Bigelow, L, Wyatt, RJ. 1982 Clonazepam treatment of chronic schizophrenia: negative results in a double-blind, placebo-controlled trial. Am J Psychiatry 139: 1627–1628Google Scholar
Kemp, R, Hayward, P, Applewhaite, G, Everitt, A, David, A. 1996 Compliance therapy in psychotic patients: randomised controlled trial. Br Med J 312: 345–349Google Scholar
Kessler, RC. 1994 Lifetime and 12 month prevalence of DSMIIIR psychiatric disorders in the United States: results from the National Co-morbidity Survey. Arch Gen Psychiatry 51: 8–20Google Scholar
King, DJ, Burke, M, Lucas, RA. 1995 Antipsychotic drug-induced dysphoria. Br J Psychiatry 167: 480–482Google Scholar
Klein, E, Bental, E, Lerer, B, Belmaker, RH. 1984 Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. Arch Gen Psychiatry 41: 165–170Google Scholar
Kramer, M, Simpson, G, Maciulis, Vet al. 2007 Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 27(1): 6–14Google Scholar
Kramlinger, KG, Post, RM. 1989 Adding lithium carbonate to carbamazepine: antimanic efficacy in treatment-resistant mania. Acta Psychiatr Scand 79: 378–385Google Scholar
Kraus, T, Haack, M, Schuld, Aet al. 1999 Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 156(2): 312–314Google Scholar
Kukopulos, A, Reginaldi, D, Laddomada, P, Floric, G. 1980 Course of the manic depressive cycle and changes caused by treatment. Pharmacopsych 13: 156–167Google Scholar
Lelliott, P, Paton, C, Harrington, M, Konsolaki, M, Sensky, T, Okocha, C. 2002 The influence of patient variables on polypharmacy and combined high dose of antipsychotic drugs prescribed for in-patients. Psychiatr Bull 26: 411–414Google Scholar
Lieberman, JA, Kane, JM. 1994 Predictors of response to clozapine. J Clin Psychiatry 55(9): 126–128Google Scholar
Lindstedt, G, Nilsson, , Walinder, J, Skott, A, Ohman, R. 1977 On the prevalence, diagnosis and management of lithium induced hypothyroidism in psychiatric patients. Br J Psychiatry 130: 452–458Google Scholar
Lindstrom, LH, Persson, E. 1980 Propranolol in chronic schizophrenia controlled study in neuroleptic treated patients. Br J Psychiatry 137: 126–130Google Scholar
Little, KY, Gay, TL, Vore, M. 1989 Predictors of response to high-dose antipsychotics in chronic schizophrenics. Psychiatr Res 30: 1–9Google Scholar
Loo, H, Poirer-Littre, MF, Theron, M. 1997 Amisulpride versus placebo in the medium term treatment of negative symptoms of schizophrenia. Br J Psychiatry 170: 18–22Google Scholar
Luchins, DL. 1984 Carbamazepine in violent non-epileptic schizophrenics. Psychopharmacol Bull 20(3): 569–571Google Scholar
Mann, JJ, Kapur, S. 1994 Elucidation of the biochemical basis of the antidepressant action of electroconvulsive therapy by human studies. Psychopharmacol Bull 30(3): 445–453Google Scholar
Marder, SR, Meibach, RC. 1994 Risperidone in the treatment of schizophrenia. Am J Psychiatry 15: 825–835Google Scholar
Markowitz, JS, Candace, SB, Moore, TR. 1999 Atypical antipsychotics: pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother 33: 73–85Google Scholar
McCreadie, RG, MacDonald, IM. 1977 High-dose haloperidol in chronic schizophrenia. Br J Psychiatry 131: 310–316Google Scholar
McCreadie, RG, Flanagan, WL, McKnight, J. 1979 High-dose flupenthixol decanoate in chronic schizophrenia. Br J Psychiatry 135: 175–179Google Scholar
McEvoy, JP, Hogarty, GE, Steingard, S. 1991 Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 48: 739–745Google Scholar
Meehan, K, Zhang, F, David, Set al. 2001 A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 21(4): 389–397Google Scholar
Mehtonen, OP, Aranko, K, Malkonen, L. 1991 A survey of sudden death associated with the use of antipsychotic or antidepressant drugs. Acta Psychiatr Scand 84: 58–64Google Scholar
Meltzer, HY. 1991 The mechanism of action of novel antipsychotic drugs. Schizophr Bull 17: 263–287Google Scholar
Meltzer, HY. 1992 Treatment of the neuroleptic, non-responsive schizophrenic patient. Schizophr Bull 18: 515–542Google Scholar
Mortimer, A. 1997 Treatment of the patient with long-term schizophrenia. Adv Psychiatr Treat 3: 339–346Google Scholar
Myers, DH, Campbell, PL, Cooks, NM. 1981 A trial of propranolol in chronic schizophrenia. Br J Psychiatry 139: 118–121Google Scholar
Nutt DJ, Glue P. 1993 The neurobiology of ECT: animal studies. In: Coffey, CE, ed The Clinical Science of Electroconvulsive Therapy. Washington DC: American Psychiatric Press, pp. 213–234
Okocha, CI. 1995 Treating addiction to benzodiazepines. Hospital UpdateSeptember, pp. 396–401Google Scholar
Okocha, CI. 1996 Managing anxiety disorders in general practice. Hospital Update November, pp. 415–419Google Scholar
Okuma, T. 1983 Therapeutic and prophylactic effects of carbamazepine in bipolar disorders. Psychiatr Clin North Am 6: 147–174Google Scholar
Ostrom, Met al. 1996 Fatal overdose with citalopram. Lancet 348: 339–340Google Scholar
Paris, J. 2000 Chronic suicidality among patients with borderline personality disorder. Psychiatr Serv 53: 738–742Google Scholar
Paton, C, Okocha, CI. 2004 Risperidone long-acting injection: the first 50 patients. Psychiatr Bull 28: 12–14Google Scholar
Paton, C, Okocha, CI. 2005 Pharmacological treatment of borderline personality disorder. J Psychiatr Intensive Care Psychiatry 1: 105–116Google Scholar
Peet, M, Middlemiss, DN, Yates, RA. 1980 Pharmacokinetic interaction between propronolol and chlorpromazine in schizophrenic patients. Lancet ii: 978Google Scholar
Pereira, S, Beer, D, Paton, C. 1999 When all else fails: a locally devised structured decision process for enforcing clozapine therapy. Psychiatr Bull 23: 654–656Google Scholar
Perry, PJ, Miller, DD, Arndt, SV, Cadoret, RJ. 1991 Clozapine and norclozapine plasma concentrations and clinical response of treatment refractory schizophrenic patients. Am J Psychiatry 148: 231–235Google Scholar
Perry, PJ, Bever, KA, Arndt S, , Combs, MD. 1998 Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram. Biol Psychiatry 44: 733–738Google Scholar
Placidi, GF, Lenzi, A, Lazzerini, F, Cassano, GB, Akiskal, HS. 1986 The comparative efficacy and safety of carbamazepine versus lithium: a randomized, double-blind 3-year trial in 83 patients. J Clin Psychiatry 47: 490–494Google Scholar
Pope, HG, McElroy, SL, Keck, P, Brown, S. 1991 Valproate in the treatment of acute mania: a placebo controlled study. Arch Gen Psychiatry 48: 62–68Google Scholar
Post, RM, Uhde, TW, Roy-Byrne, PP, Joffe, RT. 1986 Antidepressant effects of carbamazepine. Am J Psychiatry 143: 29–34Google Scholar
Post, RM, Uhde, TW, Roy-Byrne, PP, Joffe, RT. 1987 Correlates of anti-manic response to carbamazepine. Psychiatr Res 21: 71–83Google Scholar
Post, RM, Rubinow, DR, Uhde, TW. 1989 Dysphoric mania: clinical and biological correlates. Arch Gen Psychiatry 46: 353–358Google Scholar
Potkin, SG, Bera, R. 1994 Plasma clozaril concentrations predict clinical response in treatment resistant schizophrenia. J Clin Psychiatry 55(9): 133–136Google Scholar
Puzynski, S, Klosiewicz, L. 1984 Valproic acid amide in the treatment of affective and schizoaffective disorders. J Affect Disord 6: 115–121Google Scholar
Quitkin, F, Rifkin, A, Klein, DF. 1975 Very high dosage versus standard dosage fluphenazine in schizophrenia: a double-blind study of non-chronic treatment refractory patients. Arch Gen Psychiatry 32: 1276–1281Google Scholar
Reus, VI. 1997 Olanzapine: a novel atypical neuroleptic agent.. Lancet 349: 1264–1265Google Scholar
Rifkin, A, Quitkin, F, Carrillo, C. 1971 Very high-dose fluphenazine for non-chronic treatment refractory patients. Arch Gen Psychiatry 25: 398–403Google Scholar
Royal College of Psychiatrists. 1995 The ECT Handbook. Council Report CR 39. London: Royal College of Psychiatrists
Sackeim, HA. 1994 Central issues regarding the mechanisms of action of ECT: directions for future research. Psychopharmacol Bull 30(3): 281–312Google Scholar
Sackeim, HA, Prudic, J, Devanand, DP, Decina, P, Kerr, B, Malitz, S. 1990 The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. J Clin Psychopharmacol 10: 96–104Google Scholar
Sackeim, HA, Prudics, Devonod DP. 1993 Effects of stimulus intensity and electrode placement on the efficacy and cognitive effect of electroconvulsive therapy. N Engl J Med 328: 839–846Google Scholar
Salzman, C. 1980 The use of ECT in the treatment of schizophrenia. Am J Psychiatry 137: 1032–1041Google Scholar
Schooler, JVR. 1991 Maintenance medication for schizophrenia: strategic for dose reduction. Schizophr Bull 17: 311–324Google Scholar
Sernyak, MJ, Leslie, DL, Alarcon, RD, Losonczy, MF, Rosenheck, R. 2002 Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 159(4): 561–566Google Scholar
Sharif, Z. 1998 Treatment of refractory schizophrenia: how should we proceed?Psychiatr Q 69(4): 263–281Google Scholar
Sharma, R, Trappler, B, Ng, YK, Leeman, CP. 1995 Risperidone induced neuroleptic malignant syndrome. Ann Pharmacother 30: 775–778Google Scholar
Siris, S, Bermonzohn, PC, Gonzalez, A, Manson, SE. 1991 Use of antidepressants for negative symptoms in a subset of schizophrenic patients. Psychopharmacol Bull 27: 331–335Google Scholar
Small, JG, Klapper, MH, Kellams, JJ. 1988 Electroconvulsive treatment compared with lithium in management of manic states. Arch Gen Psychiatry 45: 727Google Scholar
Small, JG, Klapper, MH, Milstein, V. 1991 Carbamazepine compared with lithium in treatment of mania. Arch Gen Psychiatry 48: 915–921Google Scholar
Squire, LR. 1986 Memory functions as affected by electroconvulsive therapy. Ann N Y Acad Sci USA 462: 307–314Google Scholar
Tandon, R, Harrigan, E, Zorn, SH. 1997 Ziprasidone: a novel antipsychotic with unique pharmacological and therapeutic potential. J Serotonin Res 4: 159–177Google Scholar
Taylor, D, Duncan, D. 1995 The use of clozapine plasma levels in optimising therapy. Psychiatr Bull 19: 753–755Google Scholar
Tennent, G, Bancroft, J, Cass, J. 1974 The control of deviant sexual behaviour by drugs: a double blind controlled study of benperidol, chlorpromazine, and placebo. Arch Sex Behar 3: 261–271Google Scholar
The Concise Oxford Dictionary. 1995 9th edn. Oxford: Oxford University Press
Thompson, C. 1994 The use of high-dose antipsychotic medication. Br J Psychiatr 164: 448–458Google Scholar
Tohen, M, Zhang, F, Taylor, CCet al. 2001 A meta-analysis of the use of typical antipsychotic agents in bipolar disorder. J Affect Disord 65(1): 85–93Google Scholar
Tollefson, GD, Beasley, CM Jr, Tran, PV. 1997 Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective, and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154: 457–465Google Scholar
Watkins, SE, Callender, K, Thomas, DR, Tidmarsh, SF, Shaw, DM. 1987 The effect of carbamazepine and lithium on remission from affective illness. Br J Psychiatry 150: 180–182Google Scholar
Weiner, RD. 1994 Treatment optimization with ECT. Psychopharmacol Bull 30(3): 313–320Google Scholar
Weissman, MM, Merikangas, KR. 1986. The epidemiology of anxiety and panic disorders. J Clin Psychiatry Suppl 47: 11–17Google Scholar
West, ED. 1981 Electric convulsion therapy in depression: a double blind controlled trial. Br Med J 282: 355–357Google Scholar
Wilson, WH, Claussen, AM. 1994 Seizures associated with clozapine treatment in a state hospital. J Clin Psychiatry 55: 184–188Google Scholar
Winston, M. 2000 Recent developments in borderline personality disorder. Adv Psychiatr Treat 6: 211–218Google Scholar
Wolkowitz, OM, Tureksky N, , Reus, VI. 1992 Benzodiazepine augmentation of neuroleptics in treatment resistant schizophrenia. Psychopharmacol Bull 28: 291–295Google Scholar
Yatham, LN. 2003 Acute and maintenance treatment of bipolar mania: the role of atypical antipsychotics. Bipolar Disorders 5(S2): 7–19Google Scholar
Yorkston, NJ, Zaki, SA, Pitcher, DR, Gruzelier, JH, Hollander, D, Sergeant, HGS. 1977 Propranolol as an adjunct to the treatment of schizophrenics. Lancet ii: 575–578Google Scholar
Zanarini, MC, Frankenburg, FR. 1997 Pathways to the development of borderline personality disoder. J Personal Disord 11(1): 93–104Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×